Michael K. Davies Boeken

In this special issue, a number of internationally renowned cardiologists discuss key issues regarding current and future approaches to the management of heart failure, with special emphasis on angiotensin-converting enzyme (ACE) inhibitors. One of the articles examines the importance of ventricular remodelling, focussing on a number of different cardiac conditions. Other contributions present recent studies on the role of ACE inhibitors in preventing the progression of heart failure and in treating postmyocardial infarct patients. Consideration is also given to controversial issues, such as the optimal dose for short- and long-acting ACE inhibitors, and their effect on arrhythmias. In addition, the diagnostic methods used in everyday practices as well as the cost-effectiveness of current therapies are evaluated. The findings presented here show that ACE inhibitors are a potent yet cost-effective means not only to treat patients with both symptomatic and asymptomatic left ventricular dysfunction, but also to reduce mortality and to improve the quality of life.